Реестр препаратов-кандидатов для лечения и профилактики COVID-19
Интерферон бета-1b обладает противовирусной и иммуномодулирующей активностью.
Canakinumab is a human monoclonal antibody targeted at interleukin-1 beta. It has no cross-reactivity with other members of the interleukin-1 family, including interleukin-1 alpha.
Clevudine is an antiviral nucleoside analog drug. Upon entry into the cell, it is phosphorylated to its active state where it is incorporated into viral DNA in competition with the common nucleotide thymidine. Incorporation by viral polymerase leads to early DNA chain termination and thus non-viable viral progeny.
Cobicistat inhibits the human CYP3A proteins, which are known to degrade important antiretroviral molecules. Cobicistat is thus importantly used in combination with other drugs to help enhance their efficacy.
Cobicistat is effectively eliminate the anti-HIV activity of ritonavir while preserving its inhibitory effects on the CYP3A isozyme family of proteins. Cobicistat is therefore able to increase plasma concentration of other coadministered anti-HIV drugs without the risk of causing cobicistat-resistant mutations in the HIV virus.
FDA-approved since 2015, approved to treat HIV-1 infection.
Кортикостероиды - гормоны коры надпочечников применяются как:
- заместительная терапия
Levilimab (formerly BCD 089) is a fully human antibody acting against the interleukin-6 receptor (IL-6R) being developed for the treatment of Rheumatoid arthritis.
Зарегистрирован в РФ по ускоренной процедуре согласно Постановлению Правительства РФ от 3 апреля 2020 г. № 441.
Investigational Humanized Monoclonal Antibody to the Chemokine Receptor CCR5. Leronlimab may enhance immune response while mitigating cytokine storm.
The first as a combination therapy with HAART for HIV-infected patients and the second is for metastatic triple-negative breast cancer. Leronlimab is an investigational humanized IgG4 mAb that blocks CCR5, a cellular receptor that is important in HIV infection, tumor metastases, and other diseases, including NASH. Leronlimab has completed nine clinical trials in over 800 people, including meeting its primary endpoints in a pivotal Phase 3 trial (leronlimab in combination with standard antiretroviral therapies in HIV-infected treatment-experienced patients).
Losartan is a selective, competitive angiotensin II receptor type 1 (AT1) antagonist, reducing the end organ responses to angiotensin II. Losartan administration results in a decrease in total peripheral resistance (afterload) and cardiac venous return (preload). All of the physiological effects of angiotensin II, including release of aldosterone, are antagonized in the presence of losartan. Reduction in blood pressure occurs independently of the status of the renin–angiotensin system. As a result of losartan dosing, plasma renin activity increases due to removal of the angiotensin II feedback.
Lopinavir and ritonavir may bind to Mpro, a key enzyme for coronavirus replication. This may suppress coronavirus activity.